Neonc Technologies Holdings, INC S-1 registration statements

NeOnc Technologies Holdings, Inc. reports significant losses and a going concern warning, while advancing multiple brain cancer drug candidates and securing recent financing.

NeOnc Technologies Holdings, Inc. reports significant net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidates NEO100 and NEO212 in clinical trials and acquiring new AI and 3D bioprinting platforms.

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company focused on brain cancers, has filed an S-1 registration statement to facilitate the resale of shares tied to a potential $50 million equity line of credit, while disclosing significant financial losses and a 'going concern' warning from its auditors.

NeOnc Technologies is registering the resale of up to 5.7 million shares of its common stock by existing stockholders following its direct listing on the Nasdaq Global Market.

NeOnc Technologies Holdings is set to pursue a direct listing on the Nasdaq Global Market, offering 2,101,313 shares for resale by existing stockholders.

NeOnc Technologies has engaged RBW Capital Partners for financial advisory services related to its direct listing on Nasdaq and a private placement of common stock.

NeOnc Technologies Holdings, Inc. updates its bylaws, outlining stockholder and director responsibilities, as it prepares for a direct listing on the Nasdaq Global Market.

NeOnc Technologies Holdings is seeking to raise $75 million through an initial public offering to fund clinical trials and research into novel brain cancer treatments.